ANTROQUINONOL IN METABOLIC SYNDROME

Antroquinonol, with its characteristics of interfering with the Ras-PI3K-Akt-mTOR pathway and activating AMPK, is believed to have regulatory effects on downstream lipogenesis-related proteins, such as SREBP-1.

Studies have indicated that more than half of LDL cholesterol catabolism in the body takes place via a receptor-mediated pathway. An apolipoprotein, ApoB-100, which is virtually the only protein in the LDL particle, binds with LDL receptors (LDLR) in cells before the LDL particle is taken up into the cell and metabolized. In a cellular experiment, Antroquinonol has shown effect on increasing expression of LDLR genes, suggesting that the activation of the LDL receptor results in LDL cholesterol-lowering effects.

View research publications on Antroquinonol in Metabolic Syndromes.

For more clinical trial information please visit ClinicalTrials.gov.

References

  1. Chena, Miles Chih-Ming, et al. “Effects of Antrodia Camphorata Mycelia Extract Containing Antroquinonol on Lowering Low-Density Lipoprotein Cholesterol: A Randomized Double-Blind Study.” Journal of Pharmacy and Nutrition Sciences 7 (2017): 73-80.
  2. Hsu, C. Y., et al. “Synthetic (+)‐antroquinonol exhibits dual actions against insulin resistance by triggering AMP kinase and inhibiting dipeptidyl peptidase IV activities.” British journal of pharmacology 172.1 (2015): 38-49.